Riccardo Muzzioli

Dr. Riccardo Muzzioli

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2015 in Nature Chemical Biology
Verified
Journal Article
Closed access
LBLucia Banci
Lucia Banci
Simone Ciofi-BaffoniSimone Ciofi-Baffoni
Simone Ciofi-Baffoni
KGKarolina Gajda
Karolina Gajda
RMRiccardo Muzzioli
Riccardo Muzzioli
RPRiccardo Peruzzini
Riccardo Peruzzini
JWJulia Winkelmann
Julia Winkelmann

16 December 2015 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
LBLucia Banci
Lucia Banci
FCFrancesca Camponeschi
Francesca Camponeschi
SCSimone Ciofi-Baffoni
Simone Ciofi-Baffoni
RMRiccardo Muzzioli
Riccardo Muzzioli

1 December 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
DADominik Awad
Dominik Awad
PCPham Hong Anh Cao
Pham Hong Anh Cao
TPThomas L. Pulliam
Thomas L. Pulliam
MSMeredith Spradlin
Meredith Spradlin
ESElavarasan Subramani
Elavarasan Subramani
DFDaniel E. Frigo
Daniel E. Frigo
Lipid metabolism plays a central role in prostate cancer. To date, the major focus has centered on de novo lipogenesis and lipid uptake in prostate cancer, but inhibitors of these processes have not benefited patients. A better understanding of how cancer cells access lipids once they are created or taken up and stored could uncover more effective strategies to perturb lipid metabolism and treat patients. Here, we identified that expression of adipose triglyceride lipase (ATGL), an enzyme that controls lipid droplet homeostasis and a previously suspected tumor suppressor, correlates with worse overall survival in men with advanced, castration-resistant prostate cancer (CRPC). Molecular, genetic, or pharmacologic inhibition of ATGL impaired human and murine prostate cancer growth in vivo and in cell culture or organoids under conditions mimicking the tumor microenvironment. Mass spectrometry imaging demonstrated that ATGL profoundly regulates lipid metabolism in vivo, remodeling membrane composition. ATGL inhibition induced metabolic plasticity, causing a glycolytic shift that could be exploited therapeutically by cotargeting both metabolic pathways. Patient-derived phosphoproteomics identified ATGL serine 404 as a target of CAMKK2–AMPK signaling in CRPC cells. Mutation of serine 404 did not alter the lipolytic activity of ATGL but did decrease CRPC growth, migration, and invasion, indicating that noncanonical ATGL activity also contributes to disease progression. Unbiased immunoprecipitation/mass spectrometry suggested that mutation of serine 404 not only disrupts existing ATGL protein interactions but also leads to new protein–protein interactions. Together, these data nominate ATGL as a therapeutic target for CRPC and provide insights for future drug development and combination therapies. Significance: ATGL promotes prostate cancer metabolic plasticity and progression through both lipase-dependent and lipase-independent activity, informing strategies to target ATGL and lipid metabolism for cancer treatment.

11 January 2014 in Journal of Biomolecular NMR
Verified
Journal Article
Closed access
PDF file
Simone Ciofi-BaffoniSimone Ciofi-Baffoni
Simone Ciofi-Baffoni
AGAngelo Gallo
Angelo Gallo
RMRiccardo Muzzioli
Riccardo Muzzioli
Mario PiccioliMario Piccioli
Mario Piccioli

1 November 2019 in Journal of Molecular Biology
Verified
Journal Article
Closed access
FCFrancesca Camponeschi
Francesca Camponeschi
RMRiccardo Muzzioli
Riccardo Muzzioli
SCSimone Ciofi-Baffoni
Simone Ciofi-Baffoni
Mario PiccioliMario Piccioli
Mario Piccioli
LBLucia Banci
Lucia Banci

Verified
Journal Article
Open access
PDF file
RMRiccardo Muzzioli
Riccardo Muzzioli
AGAngelo Gallo
Angelo Gallo
MIA40 and ALR of the MIA pathway mediate the import of protein precursors that form disulfides into the mitochondrial intermembrane space. This import pathway is suggested to be a linear pathway in which MIA40 first binds to the precursor via a disulfide linkage and oxidizes it. Subsequently, ALR re-oxidizes MIA40 and then ALR transfers electrons to terminal electron acceptors. However, the precise mechanism by which ALR and MIA40 coordinate translocation is unknown. With a collection of small molecule modulators (MB-5 to MB-9 and MB-13) that inhibit ALR activity, we characterized the import mechanism in mitochondria. NMR studies show that most of the compounds bind to a similar region in ALR. Mechanistic studies with small molecules demonstrate that treatment with compound MB-6 locks the precursor in a state bound to MIA40, blocking re-oxidation of MIA40 by ALR. Thus, small molecules that target a similar region in ALR alter the dynamics of the MIA import pathway differently, resulting in a set of probes that are useful for studying the catalysis of the redox-regulated import pathway in model systems.